Sotera Health Q4 Earnings Beat Expectations with Strong Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy SHC?
Source: seekingalpha
- Earnings Beat: Sotera Health reported a Q4 non-GAAP EPS of $0.26, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential amidst market fluctuations.
- Revenue Miss: The Q4 revenue of $259.04 million, while up 8.5% year-over-year, fell short of expectations by $41.63 million, highlighting challenges from increased competition and demand variability in the market.
- Positive 2026 Outlook: The company forecasts net revenues between $1.233 billion and $1.251 billion for 2026, surpassing consensus estimates and suggesting a stable growth trajectory of 5% to 6.5% despite foreign currency impacts.
- Capital Expenditure Plans: Sotera Health plans to invest between $175 million and $225 million in capital expenditures over the next year, aimed at enhancing production capacity and technological investments to support its long-term growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SHC
Wall Street analysts forecast SHC stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.700
Low
16.00
Averages
20.42
High
24.00
Current: 15.700
Low
16.00
Averages
20.42
High
24.00
About SHC
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sotera Health Launches 25 Million Share Secondary Offering
- Secondary Offering Size: Sotera Health Company announced that certain affiliates of Warburg Pincus and GTCR are offering 25 million shares of common stock, indicating ongoing market interest in its shares.
- Company Not Selling Shares: The company stated it will not sell any shares and will not receive any proceeds, but will cover the offering expenses, reflecting its commitment to shareholder interests.
- Diverse Transaction Methods: The shares may be sold on Nasdaq, in the over-the-counter market, or through negotiated transactions at market or negotiated prices, providing flexible trading options to attract investors.
- Registration Statement Effective: The registration statement related to these shares was filed with the U.S. Securities and Exchange Commission on February 7, 2024, and became effective automatically, ensuring compliance and paving the way for the offering.
See More
Ananym Capital Management Reduces Stake in Sotera Health
- Share Reduction Details: Ananym Capital Management sold 217,684 shares of Sotera Health in Q4 2026 for an estimated $3.60 million, indicating ongoing confidence in the company despite the modest reduction in stake.
- Quarter-End Position Changes: At the end of the quarter, Ananym's total position stood at 1,192,833 shares valued at $21.04 million, reflecting a decrease of $1.15 million due to trading activities and share price fluctuations.
- Company Performance: Sotera Health achieved its 20th consecutive year of revenue growth in 2025, with net revenues nearing $1.16 billion and adjusted EBITDA rising 8% to $594 million, underscoring its critical role in the healthcare and pharmaceutical sectors.
- Future Outlook: Management projects a revenue increase of 5% to 6.5% for 2026, alongside adjusted EBITDA growth of 5.5% to 7%, highlighting the company's strategic advantages in maintaining steady demand and reliability.
See More
Ananym Capital Management Reduces Stake in Sotera Health
- Share Reduction Details: On February 17, 2026, Ananym Capital Management disclosed the sale of 217,684 shares of Sotera Health, valued at approximately $3.60 million, indicating ongoing confidence in the company despite a reduced stake of 8.65%.
- Strong Financial Performance: Sotera Health achieved nearly 6% revenue growth in 2025, reaching $1.16 billion, with net income nearly doubling to $78 million, highlighting its robust demand and market position in the medical device and pharmaceutical sectors.
- Positive Future Outlook: Management projects a revenue increase of 5% to 6.5% for 2026, alongside adjusted EBITDA growth of 5.5% to 7.0%, indicating the company's potential for sustained growth in a stable market environment.
- Investor Confidence: Although the $3.6 million trade represents a reduction, Sotera Health still constitutes nearly 9% of Ananym's portfolio, reflecting confidence in its business model and a strategic approach to risk management.
See More
Sotera Health Company Q4 2025 Earnings Call Insights
- Consistent Performance: Sotera Health achieved a 5.7% revenue increase in 2025, reaching $1.164 billion, marking 20 consecutive years of growth, which underscores the company's stability and potential in the market.
- Cash Flow Strength: Adjusted free cash flow exceeded $200 million, reflecting successful operational efficiency and cost control, further enhancing the company's financial health and investment capacity.
- Optimistic Outlook: Total revenue for 2026 is projected to reach between $1.233 billion and $1.251 billion, with a growth rate of 5% to 6.5%, indicating the company's confidence in future market demand and ongoing growth strategies.
- Management Changes: The company announced executive changes, with Alex Dimitrief transitioning to an outside adviser and Erika Ostrowski promoted to Senior Vice President and General Counsel, reflecting strategic adjustments in leadership.
See More
Sotera Health Q4 Earnings Beat Expectations with Strong Outlook
- Earnings Beat: Sotera Health reported a Q4 non-GAAP EPS of $0.26, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential amidst market fluctuations.
- Revenue Miss: The Q4 revenue of $259.04 million, while up 8.5% year-over-year, fell short of expectations by $41.63 million, highlighting challenges from increased competition and demand variability in the market.
- Positive 2026 Outlook: The company forecasts net revenues between $1.233 billion and $1.251 billion for 2026, surpassing consensus estimates and suggesting a stable growth trajectory of 5% to 6.5% despite foreign currency impacts.
- Capital Expenditure Plans: Sotera Health plans to invest between $175 million and $225 million in capital expenditures over the next year, aimed at enhancing production capacity and technological investments to support its long-term growth strategy.
See More
Irenic Capital Reduces Stake in Papa John's International
- Share Reduction Scale: Irenic Capital Management reduced its stake in Papa John's International by 748,592 shares, leaving a remaining holding of 325,108 shares valued at $12.51 million, indicating a waning confidence in the company.
- Declining Ownership Proportion: Following this reduction, Papa John's now represents only 0.8% of Irenic's assets under management, removing it from the fund's top five holdings, which reflects a significant shift in investment strategy.
- Poor Performance: Over the past year, Papa John's shares have declined by 30.7%, while the S&P 500 index has returned 16.4%, highlighting the company's lack of competitiveness in the market, which may affect future investor confidence.
- Same-Store Sales Decline: The company's same-store sales in North America fell by 2.7% in the third quarter, indicating sales challenges, prompting investors to closely monitor the upcoming fourth-quarter earnings report on February 26 for future outlook assessment.
See More
Sotera Health Launches 25 Million Share Secondary Offering
- Secondary Offering Size: Sotera Health Company announced that certain affiliates of Warburg Pincus and GTCR are offering 25 million shares of common stock, indicating ongoing market interest in its shares.
- Company Not Selling Shares: The company stated it will not sell any shares and will not receive any proceeds, but will cover the offering expenses, reflecting its commitment to shareholder interests.
- Diverse Transaction Methods: The shares may be sold on Nasdaq, in the over-the-counter market, or through negotiated transactions at market or negotiated prices, providing flexible trading options to attract investors.
- Registration Statement Effective: The registration statement related to these shares was filed with the U.S. Securities and Exchange Commission on February 7, 2024, and became effective automatically, ensuring compliance and paving the way for the offering.
See More
Ananym Capital Management Reduces Stake in Sotera Health
- Share Reduction Details: Ananym Capital Management sold 217,684 shares of Sotera Health in Q4 2026 for an estimated $3.60 million, indicating ongoing confidence in the company despite the modest reduction in stake.
- Quarter-End Position Changes: At the end of the quarter, Ananym's total position stood at 1,192,833 shares valued at $21.04 million, reflecting a decrease of $1.15 million due to trading activities and share price fluctuations.
- Company Performance: Sotera Health achieved its 20th consecutive year of revenue growth in 2025, with net revenues nearing $1.16 billion and adjusted EBITDA rising 8% to $594 million, underscoring its critical role in the healthcare and pharmaceutical sectors.
- Future Outlook: Management projects a revenue increase of 5% to 6.5% for 2026, alongside adjusted EBITDA growth of 5.5% to 7%, highlighting the company's strategic advantages in maintaining steady demand and reliability.
See More
Ananym Capital Management Reduces Stake in Sotera Health
- Share Reduction Details: On February 17, 2026, Ananym Capital Management disclosed the sale of 217,684 shares of Sotera Health, valued at approximately $3.60 million, indicating ongoing confidence in the company despite a reduced stake of 8.65%.
- Strong Financial Performance: Sotera Health achieved nearly 6% revenue growth in 2025, reaching $1.16 billion, with net income nearly doubling to $78 million, highlighting its robust demand and market position in the medical device and pharmaceutical sectors.
- Positive Future Outlook: Management projects a revenue increase of 5% to 6.5% for 2026, alongside adjusted EBITDA growth of 5.5% to 7.0%, indicating the company's potential for sustained growth in a stable market environment.
- Investor Confidence: Although the $3.6 million trade represents a reduction, Sotera Health still constitutes nearly 9% of Ananym's portfolio, reflecting confidence in its business model and a strategic approach to risk management.
See More
Sotera Health Company Q4 2025 Earnings Call Insights
- Consistent Performance: Sotera Health achieved a 5.7% revenue increase in 2025, reaching $1.164 billion, marking 20 consecutive years of growth, which underscores the company's stability and potential in the market.
- Cash Flow Strength: Adjusted free cash flow exceeded $200 million, reflecting successful operational efficiency and cost control, further enhancing the company's financial health and investment capacity.
- Optimistic Outlook: Total revenue for 2026 is projected to reach between $1.233 billion and $1.251 billion, with a growth rate of 5% to 6.5%, indicating the company's confidence in future market demand and ongoing growth strategies.
- Management Changes: The company announced executive changes, with Alex Dimitrief transitioning to an outside adviser and Erika Ostrowski promoted to Senior Vice President and General Counsel, reflecting strategic adjustments in leadership.
See More
Sotera Health Q4 Earnings Beat Expectations with Strong Outlook
- Earnings Beat: Sotera Health reported a Q4 non-GAAP EPS of $0.26, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential amidst market fluctuations.
- Revenue Miss: The Q4 revenue of $259.04 million, while up 8.5% year-over-year, fell short of expectations by $41.63 million, highlighting challenges from increased competition and demand variability in the market.
- Positive 2026 Outlook: The company forecasts net revenues between $1.233 billion and $1.251 billion for 2026, surpassing consensus estimates and suggesting a stable growth trajectory of 5% to 6.5% despite foreign currency impacts.
- Capital Expenditure Plans: Sotera Health plans to invest between $175 million and $225 million in capital expenditures over the next year, aimed at enhancing production capacity and technological investments to support its long-term growth strategy.
See More
Irenic Capital Reduces Stake in Papa John's International
- Share Reduction Scale: Irenic Capital Management reduced its stake in Papa John's International by 748,592 shares, leaving a remaining holding of 325,108 shares valued at $12.51 million, indicating a waning confidence in the company.
- Declining Ownership Proportion: Following this reduction, Papa John's now represents only 0.8% of Irenic's assets under management, removing it from the fund's top five holdings, which reflects a significant shift in investment strategy.
- Poor Performance: Over the past year, Papa John's shares have declined by 30.7%, while the S&P 500 index has returned 16.4%, highlighting the company's lack of competitiveness in the market, which may affect future investor confidence.
- Same-Store Sales Decline: The company's same-store sales in North America fell by 2.7% in the third quarter, indicating sales challenges, prompting investors to closely monitor the upcoming fourth-quarter earnings report on February 26 for future outlook assessment.
See More
